BioStrand Omics Analysis Blog:
Drug Development

Targeting Disease with Precision: A Primer on Antibody Discovery

BioStrand | March 30, 2023

The earliest reference to the potential of antibodies for treatment in humans came from an 1890...

Exploring the microbiome's impact on immunotherapy efficacy

Julie Delanote | March 1, 2023

In our previous blog post (check it out here), we explored how the microbiota can have a profound...

The microbiome- immune axis: the intersection of science and medicine

Julie Delanote | February 22, 2023

Hippocrates was quoted as saying ‘all disease starts in the gut’ and over 2000 years later...

LENSai™ - biotherapeutic intelligence for precision drug development

BioStrand | February 1, 2023

The completion of the Human Genome Project in 2003 set the stage for the modern era in precision...

Creating an AI-ready data foundation for successful AI-enabled drug discovery

BioStrand | January 25, 2023

Over the past year, we have looked at drug discovery and development from several different...

Subscribe to our blog

Computational biology and drug discovery: what to expect in 2023

Yegor Korovin | January 11, 2023

The year 2022 in computational biology was largely marked by two main advancements:

Our most widely read blogs from 2022

BioStrand | January 4, 2023

It’s been another momentous year for the global life sciences industry. Ever since the pandemic...

Notes from BioTechX 2022

Arnout Van Hyfte | December 21, 2022

I recently had the privilege of representing the BioStrand Team at BioTechX, Europe’s largest...

Precision drugs for the precision medicine era

Dr Ingrid Brands, General Manager | October 26, 2022

Currently, chemotherapy, using cytotoxic small molecules to kill cancer cells, is the predominant...

Explained: how to plot the prediction quality metrics with AlphaFold2

Sébastien Lemal PhD | October 5, 2022

In a previous blog post, we discussed the importance of AlphaFold2 (as well as other, deep-learning...

A brief retrospective on our second blogiversary

Dr Ingrid Brands, General Manager | September 21, 2022

It’s been an eventful two years, to the month, since we launched our omics and analysis blog. Our...